Smartlab Europe

Pneumococcal Vaccines Aided By New Approach By Singapore

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Novartis China Investment Expands R&D and Manufacturing

Novartis is stepping up its presence in China with...

UK Backs Respiratory Transformation Partnership with £10m

The NHS has partnered with leading pharmaceutical companies to...

The Invisible Costs Undermining Pharma Profit Margins and the Digital Fixes Gaining Traction

Pharmaceutical companies spend extraordinary amounts optimising what they can...
- Advertisement -

Numerous disease-causing bacteria like Streptococcus pneumoniae, happen to be encased in a sugar layer that is known as the capsular polysaccharide (CPS). This layer is often essential when it comes to infections.

In a discovery that can indeed be termed as ground-breaking by the scientists from the Yong Ling Lin School of Medicine of the National University of Singapore, the traits of the CPS that aid the bacteria so as to colonise the human respiratory track were pinpointed.
The study also showed that structures of the CPS capsule as well as its types of linkages and combinations, greatly matter in letting the bacteria attach better and survive on the lining of the upper and lower human respiratory tracts as well.

This inference can go on to shed more light on the CPS type range that will be a part of future vaccines since the current vaccines against S. pneumoniae do not cover the numerous types of CPS that are produced by the bacteria.

S. pneumoniae happens to be a major driver when it comes to septicaemia, pneumonia, as well as meningitis. To thwart the deadly infections, the pneumococcal vaccines are administered so as to stimulate the production of antibodies against the CPS.

That said, the bacteria can go on to manipulate their structure so as to evade the antibodies. This biochemical warfare results in more than a hundred kinds of CPSs that are produced by S. pneumoniae, which elevates the challenge when it comes to producing effective vaccines.

Latest stories

Related stories

Novartis China Investment Expands R&D and Manufacturing

Novartis is stepping up its presence in China with...

UK Backs Respiratory Transformation Partnership with £10m

The NHS has partnered with leading pharmaceutical companies to...

The Invisible Costs Undermining Pharma Profit Margins and the Digital Fixes Gaining Traction

Pharmaceutical companies spend extraordinary amounts optimising what they can...

SGD Pharma Advances Nasal Drug Delivery with Prince Deal

SGD Pharma has entered into a Franco-American OEM collaboration...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »